Vaccination in the elderly: what can be recommended? (Q38220158)

31 August 2017

title

Vaccination in the elderly: what can be recommended? (English)

1 reference

31 August 2017

Pierre-Olivier Lang

1

1 reference

31 August 2017

Richard Aspinall

series ordinal

2

1 reference

31 August 2017

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

31

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

581-599

1 reference

Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Aging, frailty and age-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Testosterone replacement therapy in reversing "andropause": what is the proof-of-principle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The immune-endocrine loop during aging: role of growth hormone and insulin-like growth factor-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Immune response of 23-valent pneumococcal polysaccharide vaccinated elderly and its relation to frailty indices, nutritional status, and serum zinc levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Assessment of vaccine candidates for persons aged 50 and older: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Immunosenescence and novel vaccination strategies for the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Immune senescence and vaccination in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The Avalanche is Coming … And Just Now It's Starting to Snow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Toll like receptor signaling in "inflammaging": microRNA as new players.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Reversing T cell immunosenescence: why, who, and how

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

"Herd immunity": a rough guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Immunosenescence: Implications for vaccination programmes in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Herd immunity and herd effect: new insights and definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Contagious diseases in the United States from 1888 to the present.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Influenza vaccine responses in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Vaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Influenza and the winter increase in mortality in the United States, 1959-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Community-acquired bacterial meningitis in elderly patients: experience over 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Rhinovirus and coronavirus infection-associated hospitalizations among older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Promoting life course vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Clinical practice: Herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Characteristics of patients with herpes zoster on presentation to practitioners in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The burden of Herpes Zoster: a prospective population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Herpes zoster eye complications: rates and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Immunity and the burden of herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Estimation of the underlying burden of pertussis in adolescents and adults in Southern Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Resurgence of pertussis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Does this coughing adolescent or adult patient have pertussis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

An epidemic of pertussis among elderly people in a religious institution in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The Age-Old Struggle against the Antivaccinationists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Willingness to vaccinate and to be vaccinated in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A systematic review of interventions for reducing parental vaccine refusal and vaccine hesitancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Declining hepatitis A seroprevalence: a global review and analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Hepatitis A virus seroprevalence by age and world region, 1990 and 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Effects of an ageing population and the replacement of immune birth cohorts on the burden of hepatitis A in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Causes of death and characteristics of decedents with viral hepatitis, United States, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The changing epidemiology of hepatitis A in Arizona following intensive immunization programs (1988-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Travel and migration associated infectious diseases morbidity in Europe, 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Travel-associated illness in older adults (>60 y).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

How long do nosocomial pathogens persist on inanimate surfaces? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Transmission of pandemic A/H1N1 2009 influenza on passenger aircraft: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Biometric fingerprinting for visa application: device and procedure are risk factors for infection transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Flu vaccination policy in old adults: need for harmonization of national public health recommendations throughout Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Impact of respiratory virus infections on persons with chronic underlying conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Inactivated influenza vaccines for prevention of community-acquired pneumonia: the limits of using nonspecific outcomes in vaccine effectiveness studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Influenza vaccine effectiveness in the community and the household

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Understanding immunosenescence to improve responses to vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

An Immune Risk Phenotype, Cognitive Impairment, and Survival in Very Late Life: Impact of Allostatic Load in Swedish Octogenarian and Nonagenarian Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Epidemiological differences among pneumococcal serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Understanding the burden of pneumococcal disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Pneumococcal Vaccination and Revaccination of Older Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Efficacy of pneumococcal vaccination in adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The next decade of vaccines: societal and scientific challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Pneumococcal vaccination in adults: does it really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Vaccines for preventing herpes zoster in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Safety and tolerability of zoster vaccine in adults ≥60 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of Tai Chi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Cost effectiveness of herpes zoster vaccine in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Efficacy of an acellular pertussis vaccine among adolescents and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

High tetanus and diphtheria antitoxin concentrations in Finnish adults--time for new booster recommendations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Hepatitis A vaccine versus immune globulin for postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Zoster vaccine: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

The continuing tensions between individual rights and public health. Talking Point on public health versus civil liberties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

A global prescription for adult immunization: Time is catching up with us

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Emergence of Vaccine-Related Pneumococcal Serotypes as a Cause of Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: No evidence of hyporesponsiveness☆☆☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0193-1

23-valent pneumococcal polysaccharide vaccine. WHO position paper

21 January 2018

1 reference

12 December 2020

Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial

1 reference

12 December 2020

Community and patient values for preventing herpes zoster

1 reference

12 December 2020

A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults

1 reference

12 December 2020

Influenza vaccination for healthcare workers who work with the elderly

1 reference

12 December 2020

Admission criteria for immunogerontological studies in man: the SENIEUR protocol

1 reference

12 December 2020

Is pertussis being considered as a cause of persistent cough among adults?

1 reference

12 December 2020

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.

1 reference

12 December 2020

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

1 reference

12 December 2020

Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia

1 reference

12 December 2020

Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older

1 reference

12 December 2020

Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.

1 reference

12 December 2020

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands

1 reference

12 December 2020

Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005

1 reference

12 December 2020

Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013.

1 reference

12 December 2020

A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults

1 reference

12 December 2020

Pertussis--a disease and vaccine for all ages

1 reference

12 December 2020

Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007

1 reference

12 December 2020

Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older

1 reference

12 December 2020

Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults

1 reference

12 December 2020

The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study

1 reference

12 December 2020

Survey of pertussis in patients with prolonged cough.

1 reference

12 December 2020

The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age

1 reference

12 December 2020

Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults

1 reference

12 December 2020

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia

1 reference

12 December 2020

Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults

1 reference

12 December 2020

Serologic immunity to diphtheria and tetanus in the United States

1 reference

12 December 2020

Vaccines for preventing pneumococcal infection in adults

1 reference

12 December 2020

Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines

1 reference

12 December 2020

Antiviral treatment for preventing postherpetic neuralgia

1 reference

12 December 2020

The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age

1 reference

12 December 2020

Tetanus surveillance --- United States, 2001-2008.

1 reference

12 December 2020

Vaccines for preventing influenza in healthy adults

1 reference

12 December 2020

Updated vaccine guidelines for aging and aged citizens of Europe

1 reference

12 December 2020

Vaccines for preventing influenza in the elderly

1 reference

12 December 2020

Protection against hepatitis A by an inactivated vaccine

1 reference

12 December 2020

Pneumococcal vaccination in adults: rationale, state of the art and perspectives

1 reference

12 December 2020

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age

1 reference

12 December 2020

Aging adults and seasonal influenza: does the vitamin d status (h)arm the body?

1 reference

12 December 2020

Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996

1 reference

12 December 2020

Vaccines for preventing pneumococcal infection in adults

1 reference

12 December 2020

Vaccines for preventing influenza in the elderly

1 reference

12 December 2020

Update on immunizations in adults.

1 reference

12 December 2020

Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands

1 reference

12 December 2020

Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study

1 reference

12 December 2020

The role of nutrition in enhancing immunity in aging

1 reference

12 December 2020

[Acute and postherpetic neuralgia in the elderly: analysis of evidence for therapeutic options]

1 reference

12 December 2020

Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013.

1 reference

12 December 2020

Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster

1 reference

12 December 2020

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials

1 reference

12 December 2020

10.1007/S40266-014-0193-1

Identifiers

DOI

1 reference

31 August 2017

1 reference